Lungs News and Research

RSS

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.

18 Sep 2010

Accuray Incorporated showcases CyberKnife VSI System at ESTRO Annual Congress

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29, the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain.

18 Sep 2010

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.

17 Sep 2010

American Lung Association data shows improvement in health benefits

The American Lung Association in California released new data today showing significant public health benefits from pursuing a smart growth future for California. The American Lung Association data shows health benefits, including reduced asthma attacks and premature deaths linked to the Vision California "mixed growth" and "growing smart" scenarios in 2035 that include more compact, sustainable development patterns.

17 Sep 2010

Scott & White Healthcare recruits patients for Phase III lung cancer trial

Scott & White Healthcare in Round Rock, Texas is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease's recurrence in previously treated patients. The trial will evaluate the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

17 Sep 2010

Scientists discover new drug target to improve radiation effectiveness for treating cancer

Scientists at Washington University School of Medicine in St. Louis have discovered a new drug target that could improve the effectiveness of radiation for hard-to-treat cancers.

17 Sep 2010

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Alpha 1 Antitrypsin Deficiency (AAT), a genetic disease known to result in serious lung and/or liver disease.

17 Sep 2010

Advocacy For Patients files free insurance appeals for consumers with chronic illness

Advocacy for Patients with Chronic Illness, Inc., one of the only organizations in America that files free insurance appeals for consumers with chronic illness nationwide - today filed comments with the United States Department of Health and Human Services, Department of Labor, and Internal Revenue Service both complimenting the Agencies for "the thoughtful approach taken by the Agencies in formulating these complex rules," and suggesting numerous improvements that should be made.

16 Sep 2010

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

NuGEN Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

16 Sep 2010

Recommendations for developing novel therapies for hypertrophic cardiomyopathy

16 Sep 2010

Key recommendations for better services for women with secondary breast cancer

The support provided for women with secondary breast cancer is inadequate and urgent steps are needed to provide better services for patients with this progressive incurable disease, which kills half a million women worldwide every year. Those are the key recommendations to emerge from a trio of papers in the September issue of the European Journal of Cancer Care.

16 Sep 2010

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT and the weight loss medication sibutramine (sold as Meridia® in the United States).

16 Sep 2010

Researchers identify mechanism to reduce pathogenic effect of bacillus bacteria

A European-Asian collaboration of scientists, notably including CNRS, the Institut Pasteur in Paris, the Institut Pasteur Korea in Seoul (IP Korea/Equipe Avenir Inserm and the Université de Toulouse have identified ten virulence genes of the tubercle bacillus. The inactivation of these genes lessens the pathogenic effects of the bacillus.

16 Sep 2010

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the introduction of five additional pharmaceutical products to its portfolio of TCM offerings.

15 Sep 2010

Researchers recommend mechanism to identify hypertrophic cardiomyopathy

An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages. So says a task force of cardiologists and cardiac biologists, headed by Thomas L. Force, M.D., James C. Wilson Professor of Medicine at Thomas Jefferson University, in the September 14th online edition of the journal Circulation.

15 Sep 2010

Smoking cessation offers favorable economic benefits to California

15 Sep 2010

Actress joins UTHealth to establish 'John Ritter Research Program in Aortic and Vascular Diseases'

Actress, writer and aortic health advocate Amy Yasbeck has joined with The University of Texas Health Science Center at Houston (UTHealth) to establish the John Ritter Research Program in Aortic and Vascular Diseases (JRRP) to combat the devastating disease that took the life of her husband, legendary comic actor John Ritter.

15 Sep 2010

Helping smokers quit also benefits states economically

A new study released today by the American Lung Association, and conducted by researchers at Penn State University, finds that helping smokers quit not only saves lives but also offers favorable economic benefits to states. The study, titled Smoking Cessation: the Economic Benefits, provides a nationwide cost-benefit analysis that compares the costs to society of smoking with the economic benefits of states providing cessation (quit-smoking) coverage.

15 Sep 2010

Survey reveals inadequate provision for women with secondary breast cancer

57% of breast care nurses who took part in a UK survey for the charity Breast Cancer Care feel that there is inadequate provision for women with secondary breast cancer, a progressive incurable disease that kills half a million women worldwide every year after the cancer spreads to other organs. Many said that they felt ill equipped to care for women with secondary breast cancer and that their time was dominated by meeting the needs of women with primary breast cancer.

15 Sep 2010

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

On Thursday, Sept. 16, the Stanford Cancer Center will become the first treatment center on the West Coast and the fifth in the world to offer cancer patients the TrueBeam, a machine that represents an exponential leap forward in the speed, power and precision of radiation therapy.

15 Sep 2010

Lungs News and Research

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Accuray Incorporated showcases CyberKnife VSI System at ESTRO Annual Congress

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

American Lung Association data shows improvement in health benefits

Scott & White Healthcare recruits patients for Phase III lung cancer trial

Scientists discover new drug target to improve radiation effectiveness for treating cancer

FDA grants AGTC $1M for Phase II human clinical trial in alpha-1 antitrypsin deficiency

Advocacy For Patients files free insurance appeals for consumers with chronic illness

NHLBI selects NuGEN to provide automated reagent solutions for expression profiling

Recommendations for developing novel therapies for hypertrophic cardiomyopathy

Key recommendations for better services for women with secondary breast cancer

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

Researchers identify mechanism to reduce pathogenic effect of bacillus bacteria

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

Researchers recommend mechanism to identify hypertrophic cardiomyopathy

Smoking cessation offers favorable economic benefits to California

Actress joins UTHealth to establish 'John Ritter Research Program in Aortic and Vascular Diseases'

Helping smokers quit also benefits states economically

Survey reveals inadequate provision for women with secondary breast cancer

Stanford Cancer Center to use TrueBeam radiation therapy technology for cancer patients

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News